ArticleIBRO neuroscience reports2025
Ethical imperatives in the commercialization of brain-computer interfaces.
Article in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ethics of brain-computer interface in mental healthcare.Frontiers in human neuroscience · 2026Article
- From technological closed-loop to human-machine trust: a systematic review of ethical and communication challenges of brain-computer interface in elderly care.Frontiers in digital health · 2026Article
- Closed-loop neuromodulation: a paradigm shift in precision neuroscience for clinical and cognitive applications.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid commercialization of brain-computer interfaces (BCIs) raises urgent ethical and scientific challenges for human research oversight. While BCIs hold transformative potential for treating neurological disorders, their premature translation into consumer markets risks outpacing neuroscientific understanding and ethical frameworks. This essay critically examines the mismatch between commercial claims and the technical limitations of current BCI systems, decoding accuracy and biocompatibility, unresolved ethical dilemmas posed by neural data commodification and procedural risks, and the inadequacy of existing governance to address vulnerabilities in consent, privacy, and long-term safety. Responsible innovation demands proactive measures and robust public engagement to align development with societal values. Without such safeguards, the rush to commercialize BCIs risks prioritizing market interests over patient welfare and eroding public trust in neurotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.